NasdaqGS:TEMLife Sciences
New FDA Clearances for Genomics and Cardiac AI Could Be A Game Changer For Tempus AI (TEM)
Tempus AI recently secured FDA approval for a tumor-only indication for its xT CDx sequencing platform and published a multi-site validation study of its already cleared ECG-AF software for predicting one-year atrial fibrillation or flutter risk.
Together, these regulatory and clinical milestones underline Tempus AI’s push to pair large-scale genomic data with AI tools that support more precise cancer and cardiac care decisions.
Next, we’ll examine how this new tumor-only xT CDx approval...